{
    "4 17 2025": {
        "importantArticles": [
            {
                "headline": "The United States market has shown a robust performance recently, climbing 8.4% in the last week and increasing by 5.9% over the past year, with earnings anticipated to grow by 13% annually. In this favorable environment, growth companies with high insider ownership can be particularly attractive as they often signal strong internal confidence and alignment of interests between management and shareholders.",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9691",
                "source": "Simply Wall St.",
                "ticker": "HIMS",
                "title": "April 2025's Top Growth Stocks With Strong Insider Confidence",
                "url": "https://finance.yahoo.com/news/april-2025s-top-growth-stocks-113605532.html"
            },
            {
                "headline": "The United States market has shown a robust performance recently, climbing 8.4% in the last week and increasing by 5.9% over the past year, with earnings anticipated to grow by 13% annually. In this favorable environment, growth companies with high insider ownership can be particularly attractive as they often signal strong internal confidence and alignment of interests between management and shareholders.",
                "publication_date": "2025-04-17T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.9691",
                "source": "Simply Wall St.",
                "ticker": "HIMS",
                "title": "April 2025's Top Growth Stocks With Strong Insider Confidence",
                "url": "https://finance.yahoo.com/news/april-2025s-top-growth-stocks-113605532.html"
            }
        ],
        "avgScore": 0.9691,
        "pctChange": -0.051046618179057104
    },
    "4 15 2025": {
        "importantArticles": [
            {
                "headline": "SAN FRANCISCO, April 14, 2025--Hims & Hers Health, Inc. (\"Hims & Hers\", NYSE: HIMS), the leading health and wellness platform, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 5, 2025. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day.",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4404",
                "source": "Business Wire",
                "ticker": "HIMS",
                "title": "Hims & Hers to Announce First Quarter 2025 Financial Results on May 5, 2025",
                "url": "https://finance.yahoo.com/news/hims-hers-announce-first-quarter-200500480.html"
            },
            {
                "headline": "SAN FRANCISCO, April 14, 2025--Hims & Hers Health, Inc. (\"Hims & Hers\", NYSE: HIMS), the leading health and wellness platform, today announced that it will report first quarter 2025 financial results after the market closes on Monday, May 5, 2025. The company will host a live conference call to discuss the results at 5:00 p.m. ET the same day.",
                "publication_date": "2025-04-15T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.4404",
                "source": "Business Wire",
                "ticker": "HIMS",
                "title": "Hims & Hers to Announce First Quarter 2025 Financial Results on May 5, 2025",
                "url": "https://finance.yahoo.com/news/hims-hers-announce-first-quarter-200500480.html"
            }
        ],
        "avgScore": 0.4404,
        "pctChange": -0.08520021722798139
    },
    "4 4 2025": {
        "importantArticles": [
            {
                "headline": "Hims & Hers Health Inc. (HIMS) is facing increased skepticism from investors and analysts over the sustainability concerns of its core business growth. While the telehealth company has shown strong revenue expansion, questions remain about long-term profitability and customer retention. As a result, many analysts are adopting a cautious stance on HIMS stock, waiting for clearer signs of stability before making bullish calls. Let\u2019s look at key 2024 data on HIMS to understand why investors and ana",
                "publication_date": "2025-04-04T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7717",
                "source": "TipRanks",
                "ticker": "HIMS",
                "title": "Analysts Stay Cautious on HIMS Stock amid Core Business Uncertainty",
                "url": "https://finance.yahoo.com/news/analysts-stay-cautious-hims-stock-140828093.html"
            },
            {
                "headline": "Hims & Hers Health Inc. (HIMS) is facing increased skepticism from investors and analysts over the sustainability concerns of its core business growth. While the telehealth company has shown strong revenue expansion, questions remain about long-term profitability and customer retention. As a result, many analysts are adopting a cautious stance on HIMS stock, waiting for clearer signs of stability before making bullish calls. Let\u2019s look at key 2024 data on HIMS to understand why investors and ana",
                "publication_date": "2025-04-04T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.7717",
                "source": "TipRanks",
                "ticker": "HIMS",
                "title": "Analysts Stay Cautious on HIMS Stock amid Core Business Uncertainty",
                "url": "https://finance.yahoo.com/news/analysts-stay-cautious-hims-stock-140828093.html"
            }
        ],
        "avgScore": 0.7717,
        "pctChange": 0.06848790697657352
    },
    "4 3 2025": {
        "importantArticles": [
            {
                "headline": "Hims stock clawed higher Wednesday though analysts laid out low expectations for Him & Hers' branded tirzepatide.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.2732",
                "source": "Investor's Business Daily",
                "ticker": "HIMS",
                "title": "Hims Claws Back After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitch",
                "url": "https://finance.yahoo.com/m/0a24e75b-02ee-3b96-9b67-944a285506f5/hims-claws-back-after-its.html"
            },
            {
                "headline": "Hims stock clawed higher Wednesday though analysts laid out low expectations for Him & Hers' branded tirzepatide.",
                "publication_date": "2025-04-03T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.2732",
                "source": "Investor's Business Daily",
                "ticker": "HIMS",
                "title": "Hims Claws Back After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitch",
                "url": "https://finance.yahoo.com/m/0a24e75b-02ee-3b96-9b67-944a285506f5/hims-claws-back-after-its.html"
            }
        ],
        "avgScore": -0.2732,
        "pctChange": -0.07145409133099477
    },
    "4 2 2025": {
        "importantArticles": [
            {
                "headline": "Hims & Hers Health  said it is expanding its weight-loss offerings with the addition of  Eli Lilly  & Co. Zepbound and generic liraglutide.  The telehealth-consultation platform on Tuesday said it aimed to bring its customers more treatment options to best suit their needs.  \u201cWe\u2019ve now expanded that choice even further by adding access to generic liraglutide and branded tirzepatide through our platform,\u201d the company said.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.6369",
                "source": "The Wall Street Journal",
                "ticker": "HIMS",
                "title": "Hims & Hers Expands Weight Loss Offering, Adds Lilly\u2019s Zepbound to Platform",
                "url": "https://finance.yahoo.com/m/bb6ccb3d-e7be-3872-b466-d6533c76a407/hims-hers-expands-weight.html"
            },
            {
                "headline": "It is hard to get excited after looking at Hims & Hers Health's (NYSE:HIMS) recent performance, when its stock has...",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.25",
                "source": "Simply Wall St.",
                "ticker": "HIMS",
                "title": "Hims & Hers Health, Inc.'s (NYSE:HIMS) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?",
                "url": "https://finance.yahoo.com/news/hims-hers-health-inc-nyse-130223740.html"
            },
            {
                "headline": "Questions about insurance coverage for weight-loss drugs are getting more intense as cheaper alternatives go off the market.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.1513",
                "source": "The Wall Street Journal",
                "ticker": "HIMS",
                "title": "Who Should Pay for Ozempic Is the Next Big Workplace Fight",
                "url": "https://finance.yahoo.com/m/71e35cb5-1d5f-3dae-b4c3-fa6b391d490a/who-should-pay-for-ozempic-is.html"
            },
            {
                "headline": "Yahoo Finance Senior Reporter Anjalee Khemlani joins Market Domination to discuss some of the top stories of the trading day, including Johnson & Johnson's (JNJ) setback in its litigation. Additionally, Hims & Hers (HIMS) expanded its offerings, adding Eli Lilly's (LLY) GLP-1 drugs to its telehealth platform, following its earlier partnership with Novo Nordisk. To watch more expert insights and analysis on the latest market action, check out more Market Domination&nbsp;here.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Negative",
                "sentimentScore": "-0.0516",
                "source": "Yahoo Finance Video",
                "ticker": "HIMS",
                "title": "Hims & Hers adds Eli Lilly GLP-1 drugs, Johnson & Johnson setback",
                "url": "https://finance.yahoo.com/video/hims-hers-adds-eli-lilly-204847891.html"
            },
            {
                "headline": "Hims stock surged Tuesday after the compounding pharmacy said it would sell Eli Lilly's branded weight-loss drug on its telehealth platform.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Neutral",
                "sentimentScore": "0.0",
                "source": "Investor's Business Daily",
                "ticker": "HIMS",
                "title": "Hims Stock Jumps After Adding Eli Lilly's Obesity Drug To Its Platform",
                "url": "https://finance.yahoo.com/m/877a443d-016e-3f73-9182-44a3661c599e/hims-stock-jumps-after-adding.html"
            },
            {
                "headline": "Questions about insurance coverage for weight-loss drugs are getting more intense as cheaper alternatives go off the market.",
                "publication_date": "2025-04-02T00:00:00.000Z",
                "sentiment": "Positive",
                "sentimentScore": "0.1513",
                "source": "The Wall Street Journal",
                "ticker": "HIMS",
                "title": "Who Should Pay for Ozempic Is the Next Big Workplace Fight",
                "url": "https://finance.yahoo.com/m/71e35cb5-1d5f-3dae-b4c3-fa6b391d490a/who-should-pay-for-ozempic-is.html"
            }
        ],
        "avgScore": 0.19732,
        "pctChange": -0.10345930856105694
    },
    "coef": 0.6,
    "avgCoef": 0.0171241673880901,
    "similar": {
        "ERIC": 0.9999999999999999,
        "AAPL": 0.8999999999999998,
        "VALE": 0.8999999999999998,
        "AMD": 0.8999999999999998
    }
}